vs
Side-by-side financial comparison of Cheche Group Inc. (CCG) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
Cheche Group Inc. is the larger business by last-quarter revenue ($32.8M vs $28.1M, roughly 1.2× ARS Pharmaceuticals, Inc.). Cheche Group Inc. runs the higher net margin — 0.5% vs -147.1%, a 147.6% gap on every dollar of revenue.
Cheche Group Inc. is a leading automotive digital service provider headquartered in China. It offers integrated solutions including auto insurance intermediary services, smart auto after-sales support, and connected vehicle technology products, serving individual car owners, auto dealerships, and insurance partners across domestic and select Southeast Asian markets.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
CCG vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.8M | $28.1M |
| Net Profit | $153.6K | $-41.3M |
| Gross Margin | 5.7% | — |
| Operating Margin | — | -147.6% |
| Net Margin | 0.5% | -147.1% |
| Revenue YoY | — | -67.6% |
| Net Profit YoY | — | -182.8% |
| EPS (diluted) | $0.00 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $32.8M | — | ||
| Q4 25 | — | $28.1M | ||
| Q3 25 | — | $32.5M | ||
| Q2 25 | $26.0M | $15.7M | ||
| Q1 25 | — | $8.0M | ||
| Q4 24 | $18.6M | $86.6M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | $36.1M | $500.0K |
| Q1 26 | $153.6K | — | ||
| Q4 25 | — | $-41.3M | ||
| Q3 25 | — | $-51.2M | ||
| Q2 25 | $-492.4K | $-44.9M | ||
| Q1 25 | — | $-33.9M | ||
| Q4 24 | $-196.7K | $49.9M | ||
| Q3 24 | — | $-19.1M | ||
| Q2 24 | $-7.6M | $-12.5M |
| Q1 26 | 5.7% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 4.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -147.6% | ||
| Q3 25 | — | -163.7% | ||
| Q2 25 | -2.0% | -302.9% | ||
| Q1 25 | — | -466.3% | ||
| Q4 24 | -0.3% | 54.5% | ||
| Q3 24 | — | -1051.6% | ||
| Q2 24 | -4.7% | -3068.0% |
| Q1 26 | 0.5% | — | ||
| Q4 25 | — | -147.1% | ||
| Q3 25 | — | -157.4% | ||
| Q2 25 | -1.9% | -285.6% | ||
| Q1 25 | — | -425.7% | ||
| Q4 24 | -1.1% | 57.7% | ||
| Q3 24 | — | -925.0% | ||
| Q2 24 | -21.0% | -2503.2% |
| Q1 26 | $0.00 | — | ||
| Q4 25 | — | $-0.41 | ||
| Q3 25 | — | $-0.52 | ||
| Q2 25 | $-0.01 | $-0.46 | ||
| Q1 25 | — | $-0.35 | ||
| Q4 24 | $-0.00 | $0.52 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | — | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.0M | $245.0M |
| Total DebtLower is stronger | $193.3K | $96.4M |
| Stockholders' EquityBook value | — | $114.3M |
| Total Assets | $203.5M | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $20.0M | — | ||
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | $23.1M | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | $21.1M | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | $28.2M | $218.7M |
| Q1 26 | $193.3K | — | ||
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | $690.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $114.3M | ||
| Q3 25 | — | $147.7M | ||
| Q2 25 | $47.1M | $192.3M | ||
| Q1 25 | — | $229.0M | ||
| Q4 24 | $49.1M | $256.8M | ||
| Q3 24 | — | $201.0M | ||
| Q2 24 | $48.6M | $215.2M |
| Q1 26 | $203.5M | — | ||
| Q4 25 | — | $327.7M | ||
| Q3 25 | — | $372.8M | ||
| Q2 25 | $177.3M | $313.5M | ||
| Q1 25 | — | $327.3M | ||
| Q4 24 | $177.7M | $351.2M | ||
| Q3 24 | — | $217.6M | ||
| Q2 24 | $139.3M | $222.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-43.5M | ||
| Q3 25 | — | $-47.0M | ||
| Q2 25 | $-44.7M | $-39.6M | ||
| Q1 25 | — | $-40.7M | ||
| Q4 24 | $-15.8M | $42.0M | ||
| Q3 24 | — | $-14.5M | ||
| Q2 24 | $-1.0K | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | $-16.0M | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | $-1.1K | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | -85.9% | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | -0.0% | -1463.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | 1.2% | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | 0.0% | 7.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCG
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
